Emavusertib, a dual IRAK4-FLT3 inhibitor, demonstrated strong preclinical and clinical activity in NHL, CLL, and AML, with deeper and more durable responses than current standards, especially in PCNSL and mFLT3 AML. Safety profile is favorable, and registrational studies are ongoing.

Original document:

This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.